DexCom (NASDAQ:DXCM) Shares Gap Down to $138.01

DexCom, Inc. (NASDAQ:DXCM)’s share price gapped down before the market opened on Friday . The stock had previously closed at $138.01, but opened at $132.50. DexCom shares last traded at $130.57, with a volume of 1,759,920 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on DXCM shares. Citigroup boosted their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Canaccord Genuity Group boosted their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday. UBS Group boosted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd. Finally, Raymond James boosted their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $141.67.

DexCom Stock Performance

The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. The firm’s 50 day moving average is $131.13 and its 200-day moving average is $118.53. The firm has a market cap of $49.24 billion, a price-to-earnings ratio of 80.22, a price-to-earnings-growth ratio of 2.37 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.38%. Sell-side analysts anticipate that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the transaction, the executive vice president now owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Sadie Stern sold 20,321 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Jon Brown sold 2,624 shares of the company’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the transaction, the executive vice president now directly owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The disclosure for this sale can be found here. Insiders sold a total of 189,375 shares of company stock valued at $25,530,859 in the last quarter. Insiders own 0.41% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Stableford Capital II LLC raised its position in shares of DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after buying an additional 88 shares during the last quarter. D Orazio & Associates Inc. raised its position in shares of DexCom by 0.8% during the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after buying an additional 93 shares during the last quarter. Gulf International Bank UK Ltd raised its position in shares of DexCom by 0.3% during the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after buying an additional 93 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in DexCom by 10.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after acquiring an additional 98 shares during the period. Finally, Harbor Investment Advisory LLC increased its stake in DexCom by 13.1% in the first quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock valued at $120,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.